Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 65 | AmgenINDUSTRY | 2 | Jul 13, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 66 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | terminated | Phase 2 | 342 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 11 | NYU Langone HealthOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP(SMR-3184) | terminated | Phase 1 / Phase 2 | 1 | Allarity TherapeuticsINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT04243109 | Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib(POCODEX) | terminated | Phase 2 | 6 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02112045 | A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation | terminated | Phase 2 | 90 | Washington University School of MedicineOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00765102 | Trial of Romidepsin and Bortezomib for Multiple Myeloma | terminated | Phase 2 | 32 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT01248455 | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 48 | Ashraf BadrosOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01783522 | Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib | terminated | Phase 2 | 9 | Beth FaimanOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia(8400-401) | terminated | Phase 1 / Phase 2 | 31 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | terminated | Phase 2 | 57 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 1 | Yvonne EfeberaOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 81 | Seagen Inc.INDUSTRY | 1 | May 17, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | terminated | Phase 2 | 34 | Prothena Biosciences Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | terminated | Phase 2 | 10 | Gilead SciencesINDUSTRY | 1 | May 14, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | terminated | Phase 2 | 24 | Seagen Inc.INDUSTRY | 2 | Mar 11, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | terminated | Phase 2 | 24 | Sirtris, a GSK CompanyINDUSTRY | 2 | Feb 27, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | terminated | Phase 1 / Phase 2 | 6 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 14 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)(BENEFIT) | terminated | Phase 2 | 21 | Centre Leon BerardOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | terminated | Phase 2 | 105 | Gilead SciencesINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma | terminated | Phase 2 | 11 | Lymphoma Study AssociationOTHER | 0 | Aug 23, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2020source: clinicaltrials